Please assess the completion status of the following clinical trial:

Trial Title: Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients aged 18 to 90 years old~* Patients either with :~  * Portal cavernoma radiologically confirmed, treated or not by anticoagulant~ * previous history of acute portal thrombosis for more than 6 months confirmed by angio-TDM or angio-MRI, repermeabilized or not~* prophylaxis of gastro-intestinal bleeding due to portal hypertension, as recommended for cirrhosis patients. Upper gastro-intestinal endoscopy for less than 12 months~* clinical examination~* for women of childbearing age, contraception, either mecanichal or intra-uterin device, or oral progestative alone. No oral oestroprogestative contraception is allowed.~* written informed consent~* covered by a social security scheme or French CMU~Exclusion Criteria:~* At least one High risk factors of thrombosis recurrence after review by the committee composed of an hepatologist and an hematologist specialist of hemostasis~* Cirrhosis clinically or histologically confirmed or Budd-Chiari syndrome~* Any disease leading to significant coagulopathy and clinically significant bleeding risk (platelets \<50 000, or PT \<30% without VKA, or Factor V \<30% or Fibrinogen \<0,8).~* Personal or familial (1rst degree) history of spontanaeous deep vein thrombosis requiring anticoagulant treatment~* pregnant or breast-feeding women~* History of mesenteric veinous ischemia leading to intestinal resection~* patient infected by HIV and treated by anti-protease~* Formal indication to anticoagulant treatment for any reason~* No possible follow-up~* severe renal injury (creatinin clearance \<30 ml/min)~* Patients receiving a systemic treatment by azoled antifongic agent (such as ketoconazole, itraconazole, voriconazole or posaconazole), or a protease inhibitor. These are strong CYP3A4 and P-gp inhibitors.~* Patients receiving a systemic treatment by rifampicyn or any other strong CYP3A4 inducting/stimulator (phenytoïne, carbamazepine, phenobarbital or millepertuis/Hypericum perforatum)~* Hypersensitvity to rivaroxaban or excipients~* active bleeding, or any condition at risk for significant major bleeding~* Any other concomitant anticoagulant treatment, such as non-fractionnaed heparin, low-molecular weight heparin (enoxaparin, dalteparine, etc...), heparin derivatives (fondaparinux, etc), oral anticoagulant (warfarine, dabigatran etexilate, apixaban, etc) except in case of switch to Xarelto® or, in case of non-fractionnaed heparin administered to maintain central veinous or arterial catheterism permeability~* Concomitant treatment by clopidogrel / Plavix® for acute coronary syndrome~* hepatic transplantation~* Intra-hepatic shunt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Xarelto (Type: EXPERIMENTAL): 15mg/day oral administration during 2 to 4 years (based on the recruitment date).
- untreated (Type: NO_INTERVENTION): the patient won't receive any treatment during his study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).